<DOC>
	<DOCNO>NCT00846027</DOCNO>
	<brief_summary>This single-arm study assess efficacy safety first-line treatment Avastin ( bevacizumab ) combination taxane-based chemotherapy ( paclitaxel gemcitabine ) patient HER-2 negative breast cancer . Patients receive Avastin 10 mg/kg iv , paclitaxel 150 mg/m^2 iv , gemcitabine 200 mg/m^2 iv Day 1 Day 15 4-week treatment cycle disease progression , death , withdrawal consent .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Combination With Taxane-based Chemotherapy First Line Treatment Patients With HER-2 Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Female patient , ≥ 18 year age . Breast cancer , measurable , locally recurrent metastatic lesion , patient bone metastasis . HER2 negative disease . Candidates chemotherapy . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . Previous chemotherapy metastatic locally advanced breast cancer . Previous radiotherapy treatment metastatic breast cancer . Any prior adjuvant treatment anthracyclines complete &lt; 6 month prior enrollment . Chronic daily treatment corticosteroid ( ≥ 10 mg/day ) , aspirin ( &gt; 325 mg/day ) clopidogrel ( &gt; 75mg/day ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>